Tel Aviv’s Compugen Announced Multi-Year Research Collaboration with Johns Hopkins University, School of Medicine.
http://www.israel21c.org/news/compugen-teams-with-johns-hopkins-university-on-immune-checkpoints/
Compugen teams with Johns Hopkins University on immune checkpoints
Tel Aviv’s Compugen has announced the initiation of a multi-year
research collaboration with Johns Hopkins University, School of
Medicine, on immune checkpoint candidates for the potential treatment
of cancer.
This collaborative research will expand Compugen’s ongoing assessment
of the biology and mechanism of actions of its novel B7/CD28-like
immune checkpoint proteins, and provide access to the world-class
immuno-oncology research tools and expertise at Johns Hopkins
University.
The project will be under the direction of Prof. Drew Pardoll and Dr.
Charles Drake, members of Compugen’s Scientific Advisory Board, and
well known pioneers in the field of immuno-oncology.
“We are very enthusiastic to be collaborating with them and with Johns
Hopkins University in this comprehensive research program to further
characterize and differentiate our novel cancer immunotherapy
B7/CD28-like candidates. We anticipate that this research will provide
important insights for the continuing development by us and our
potential future partners of our therapeutic candidates in the
exceptionally promising field of cancer immunotherapy,” said Dr. Anat
Cohen-Dayag, President and CEO of Compugen, a leading drug discovery
company focused on therapeutic proteins and monoclonal antibodies to
address important unmet needs in the fields of oncology and
immunology.
Immune checkpoints, which are “hijacked” by tumors to block the
ability of the immune system to destroy the tumor have lately emerged
as “game changers” and promising targets for cancer immunotherapy.
“Immunotherapy is dramatically changing the landscape for cancer
treatment, but current therapies appear to address only a small
percentage of patients. It is widely believed that the availability of
monoclonal antibody drugs addressing additional checkpoint targets
will significantly broaden the applicability of this breakthrough
approach. Therefore, the large number of novel checkpoint candidates
discovered to date by Compugen represents a potential major
contribution to this rapidly growing field,” said Dr. Drake.
Comments are closed.
